Back To The Well: Rebate Reform Rule Delay Would Fund Senate Gun Control Bill Provisions
For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.
You may also be interested in...
US Senate’s updated version of drug pricing legislation is even worse for industry when it comes to the proposed price ‘negotiation’ authority, a Congressional Budget Office analysis indicates. The big numbers facing the industry just keep getting bigger.
Latest version of Medicare price negotiation and price inflation rebate provisions are expected to lower federal government costs by about $200bn over 10 years.
Commission policy statement highlights situations where rebates lead to formulary exclusion of lower-priced insulin. But concern is also relevant for other drug classes, including highly-anticipated coverage decisions for biosimilars to Humira.